World Economic Forum Selects Phase Forward as Technology Pioneer 2009
Phase Forward, a provider of data management solutions for clinical trials and drug safety, today announced that it has been selected as a Technology Pioneer 2009 by the World Economic Forum.
Innovators Recognized for Business and Societal Impact; 34 Visionary Companies Honored from Among 320 Applicants
Waltham, Mass. – December 4, 2008 – Phase Forward <
The World Economic Forum characterizes Technology Pioneers <
“It is a great honor for Phase Forward to be recognized by an organization whose mission is nothing less than improving the state of the world,” said Weiler. “On behalf of the Phase Forward team, we enter 2009 with a renewed sense of purpose to work with our customers to get life-changing therapies to market more quickly and safely.”
“We congratulate the 34 newly selected Technology Pioneers for their remarkable achievements and welcome them to the wider community of the World Economic Forum. During these difficult times, we are certain that the technologies driven by these visionary companies will contribute to the next wave of growth, with the innovative and entrepreneurial spirit that characterizes them,” said André Schneider, Managing Director and Chief Operating Officer of the World Economic Forum.
“We’re proud to have an innovative company like Phase Forward representing our state at this prestigious international forum,” said Dan O’Connell, Massachusetts Secretary of Housing and Economic Development. “Phase Forward’s unique innovation – developing software to automate the clinical trial process – successfully translated a concept into a vibrant, publicly held company. Companies like Phase Forward underscore Massachusetts’ position as a global leader in life sciences and technology.”
This recognition represents the culmination of a remarkable year for Phase Forward. The company ranked 38th on the Fortune “Small Business 100” list of America’s fastest growing small public companies, and ranked 16th in the Boston Globe “Globe 100” of top-performing public companies in Massachusetts. The company’s InForm™ Integrated Trial Management product was named by the Software & Information Industry Association as the winner of the 2008 CODiE Award for Best Medical and Health Information Product. Phase Forward customer GSK won a prestigious Wall Street Journal Technology Innovation Award for a software system that helps to predict safety issues in early-stage pharmaceutical research. The system was co-developed by GSK and Phase Forward’s Lincoln Safety Group. And another Phase Forward customer, Dana-Farber Cancer Institute, won CIO Magazine’s 2008 CIO 100 award for its implementation of Phase Forward’s flagship InForm product.
About the World Economic Forum Technology Pioneers Program
This is the 10th anniversary of the Technology Pioneers program of the Forum, which aims to recognize companies at the forefront of technology and innovation. The program, started in 2000, so far has identified around 400 companies that have contributed to the Forum’s mission of improving the state of the world. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership and show all the signs of being a long-standing market leader – and its technology must be proven. Previous Technology Pioneers include 23andme, Amyris Biotechnologies, Dr. Reddy Laboratories, Google, Gridpoint, Infosys, Kaspersky Lab, Mozilla Corporation and Nanosolar.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (Empirica Signal™) and Signal Management, adverse event reporting (Empirica Trace™), applied data standards (WebSDM™) and Web-integrated interactive response technologies (Clarix™). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025